- Home
- Equipment
- usa new york
- drug design with structure based drug design
Show results for
Refine by
Drug Design With Structure Based Drug Design Equipment Supplied In Usa New York
8 equipment items found
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TNX-2900, Tonix’s proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage as a candidate for the treatment of Prader-Willi syndrome (PWS) and non-organic failure to thrive disease. TNX-2900 has been granted Orphan Drug Designation (ODD) in the US by the FDA for the treatment of ...
Manufactured by:Alfa Chemistry based inNY, NEW YORK (USA)
Introducing fluorine atom(s) into bioactive organic compounds has become a leading strategy for drug design and lead optimization. In drug synthesis strategy, fluorine is frequently employed to modify biologically relevant properties such as metabolic stability, basicity, lipophilicity and bioavailability. Additionally, the binding affinity of compounds to biological targets may also improve upon ...
by:Curemark based inRye Brook, NEW YORK (USA)
The U.S. Centers for Disease Control and Prevention estimate that 1 in 68 children in the United States have been diagnosed with Autism. There is currently no approved drug on the market that treats the core symptoms of Autism. At Curemark, we are working to change that. Curemark’s lead drug candidate, CM-AT, has received “Fast Track” designation from the U.S. Food and Drug ...
Manufactured by:ENB Therapeutics based inNew York, NEW YORK (USA)
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which is required for T-cells to leave the circulation and infiltrate the tumor. Activated T cells are then able to infiltrate the tumor and kill ...
Manufactured by:Benevolent based inLondon, UNITED KINGDOM
The Benevolent Platform™ is our powerful computational R&D platform. At its core sits our Knowledge Graph, which captures the interconnectivity of all relevant available data and scientific literature. Our suite of exploratory and predictive AI tools allow scientists to interrogate the data and disease networks within the graph, ask biological questions, surface novel ...
by:Valo Health, Inc. based inBoston, MASSACHUSETTS (USA)
Opal is the first end-to-end integrated drug discovery & development platform. Traditional, linear approaches to target discovery and drug development have created sub-optimized systems that are intrinsically disintegrated and ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is currently in a Phase I clinical trial to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and in development to ...
Manufactured by:Protara Therapeutics, Inc. based inNew York, NEW YORK (USA)
IV choline chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy initially in development for patients receiving parenteral nutrition (PN) who have intestinal failure-associated liver disease (IFALD). Choline is a known important substrate for phospholipids that are critical for healthy liver function. Because PN patients cannot sufficiently absorb ...